the benefits of glp 1 drugs beyond obesity Unstoppable Rise GLP-1 Agonists: Revolutionising Diabetes and Treatment GLP-1 drugs calm inflammation beyond
Description
179 (6):1276-1288.e1214 133
However, there are some rare but serious risks, including pancreatitis and gallbladder issues
Risk of Retained Gastric Contents in Patients Using GLP-1RAs or Tirzepatide Presenting for Endoscopy or General Anesthesia Retrospective studies suggest that individuals on GLP-1-based therapy (exenatide, liraglutide, dulaglutide, semaglutide, or tirzepatide) appear to be at an increased risk of having retained gastric contents [Supplementary Table S3 (21)
doi: 10.1093/haschl/qxae055
Statements Author contributions GM: Writing review & editing, Writing original draft
GLP-1 agonists work on brain reward pathways and appetite regulation centers, potentially reducing the hedonic or reward-driven aspects of eating
